ArticleCancer medicine2024
A clinical-radiomic-pathomic model for prognosis prediction in patients with hepatocellular carcinoma after radical resection.
Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- A multimodal study on predicting extrathyroidal extension of papillary thyroid carcinoma based on radiopathomics.BMC endocrine disorders · 2026Article
- Multimodal data-driven prediction of postoperative recurrence and survival in hepatocellular carcinoma: a narrative review.Journal of gastrointestinal oncology · 2026Review
- A Pathomics-Based Prognostic Model for Disease-Free Survival in Resected Gastric Cancer.Cancers · 2026Article
- Dynamic Vascular Spatiotemporal Heterogeneity on Multiphase CT for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Article
- Artificial intelligence-driven pathomics in hepatocellular carcinoma: current developments, challenges and perspectives.Discover oncology · 2025Review
- Multimodal fusion model for prognostic prediction and radiotherapy response assessment in head and neck squamous cell carcinoma.NPJ digital medicine · 2025Article
- Radiomics and molecular analysis: Bridging the gap for predicting hepatocellular carcinoma prognosis.World journal of clinical cases · 2025Article
- A clinical-radiomic-pathomic model for prognosis prediction in patients with hepatocellular carcinoma after radical resection.Cancer medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeRadical surgery, the first-line treatment for patients with hepatocellular cancer (HCC), faces the dilemma of high early recurrence rates and the inability to predict effectively. We aim to develop and validate a multimodal model combining clinical, radiomics, and pathomics features to predict the risk of early recurrence. MATERIALS AND
methodsWe recruited HCC patients who underwent radical surgery and collected their preoperative clinical information, enhanced computed tomography (CT) images, and whole slide images (WSI) of hematoxylin and eosin (H & E) stained biopsy sections. After feature screening analysis, independent clinical, radiomics, and pathomics features closely associated with early recurrence were identified. Next, we built 16 models using four combination data composed of three type features, four machine learning algorithms, and 5-fold cross-validation to assess the performance and predictive power of the comparative models.
resultsBetween January 2016 and December 2020, we recruited 107 HCC patients, of whom 45.8% (49/107) experienced early recurrence. After analysis, we identified two clinical features, two radiomics features, and three pathomics features associated with early recurrence. Multimodal machine learning models showed better predictive performance than bimodal models. Moreover, the SVM algorithm showed the best prediction results among the multimodal models. The average area under the curve (AUC), accuracy (ACC), sensitivity, and specificity were 0.863, 0.784, 0.731, and 0.826, respectively. Finally, we constructed a comprehensive nomogram using clinical features, a radiomics score and a pathomics score to provide a reference for predicting the risk of early recurrence.
conclusionsThe multimodal models can be used as a primary tool for oncologists to predict the risk of early recurrence after radical HCC surgery, which will help optimize and personalize treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.